reports
Stryker Corp: 1 director
A director at Stryker Corp sold 230,000 shares at 367.370USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Edwards Lifesciences Corp: 1 director
A director at Edwards Lifesciences Corp sold 25,000 shares at 65.915USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Stryker reports third quarter 2024 operating results
Stryker reports third quarter 2024 operating results Portage, Michigan, Oct. 29, 2024 (GLOBE NEWSWIRE) -- reported operating results for the third quarter of 2024: Third Quarter Results Reported net sales increased 11.9% to $5.5 billionOrganic net sales increased 11.5%Reported operating income margin of 19.7%Adjusted operating income margin(1) increased 130 bps to 24.7%Reported EPS increased 20.0% to $2.16Adjusted EPS(1) increased 16.7% to $2.87 Third Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Ne...
Edwards Lifesciences Reports Third Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Sept. 30, 2024. Highlights and Outlook Q3 sales from continuing operations grew 9%; constant currency1 sales grew 10% Q3 TAVR sales grew 6%; constant currency1 sales grew 7% TMTT sales grew 73%; PASCAL and EVOQUE commercial launches continue to progress well Q3 EPS of $5.13; adjusted1 EPS of $0.67 Completed sale of Critical Care in Q3, resulting in significant one-time gain Pivotal TAVR and TMTT clinical evidence to be presented next week at TCT Completed enro...
Edwards Lifesciences to Host Earnings Conference Call on October 24, 2...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at . About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structural heart...
Stryker completes acquisition of care.ai
Stryker completes acquisition of care.ai Portage, Michigan, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), announced that it has completed the previously announced acquisition of care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. “We welcome the care.ai team to Stryker and look forward to working together to accelerate our digital vision to provide customers with real-time, smart and connected decision-making tools that can enhance the lives of caregivers and their patients,” ...
Moody's Ratings affirms Edwards Lifesciences' Baa2 ratings
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. The outlook is stable. The rating affirmation reflects our view that Edwards will continue to sustain leadership an...
Moody's Ratings affirms Edwards Lifesciences' Baa2 ratings
Moody's Ratings (Moody's) affirmed the ratings of Edwards Lifesciences Corporation (Edwards) including the Baa2 senior unsecured notes and Baa2 senior unsecured bank credit facilities. The outlook is stable. The rating affirmation reflects our view that Edwards will continue to sustain leadership ...
Moody's Ratings assigns Baa1 rating to Stryker Corporation's new senio...
Moody's Ratings assigns Baa1 ratings to Stryker Corporation's ("Stryker") proposed $1,500 million USD senior unsecured notes and €1,400 million Euro senior unsecured notes. There are no changes to the existing Baa1 senior unsecured ratings and the company's Prime-2 commercial paper rating. The outlo...
- Dave Nicoski
- Ross LaDuke
ILMN ILLUMINA INC.
KMX CARMAX INC.
TFX TELEFLEX INCORPORATED
OMCL OMNICELL INC.
MDT MEDTRONIC PLC
MD MEDNAX INC.
LAD LITHIA MOTORS INC. CLASS A
JNJ JOHNSON & JOHNSON
GILD GILEAD SCIENCES INC.
EXPE EXPEDIA GROUP INC.
CNMD CONMED CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
BXP BOSTON PROPERTIES INC.
ATSG AIR TRANSPORT SERVICES GROUP INC.
APPS DIGITAL TURBINE
ANGO ANGIODYNAMICS INC.
AMPH AMPHASTAR PHARMACEUTICALS INC
AUP AURINIA PHARMACEUTICALS INC.
CRI CARTER'S INC.
LBRDA LIBERTY BROADBAND CORP. CLASS A
ASIX ADVANSIX INC.
CSCO CISCO SYSTEMS INC.
KREF KKR REAL ESTATE FINANCE TRUST
ROKU ROKU INC. CLASS A
PGC PEAPACK-GLADSTONE FINANCIAL CORP.
ZM ZOOM VIDEO COMMUNICATIONS INC. CLASS A
NVST ENVISTA HOLDINGS
MTCH MATCH GROUP INC.
GEVO GEVO
CGEM CULLINAN ONCOLOGY INC
OLPX OLAPLEX HLDGS INC
TSE TRINSEO PLC
EXFY EXPENSIFY INC
CCI CALAMOS GLB CNVRTBL & DYNMC INC COM
CSOAD COASTAL CONTACTS INC COM
Stryker announces definitive agreement to acquire Vertos Medical, Inc....
Stryker announces definitive agreement to acquire Vertos Medical, Inc., expanding interventional pain management solutions Portage, Michigan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis. Lumbar spinal stenosis affects millions of people globally and is a leading cause of pain and disability. Patients today are seeking minimally invas...
- Dave Nicoski
- Ross LaDuke
Edwards Lifesciences to Present at the 2024 Wells Fargo Healthcare Con...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the Wells Fargo Healthcare Conference on Thursday, Sept. 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:15 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at , with an archived version accessible later the same day. About Edwards Lifesciences Edwards Lifesciences is the global leader of patient-focused innovations for structura...
Stryker to participate in the 2024 Wells Fargo Healthcare Conference
Stryker to participate in the 2024 Wells Fargo Healthcare Conference Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor. Spencer Stiles, Group President, Orthopaedics and Spine, and Jason Beach, Vice President, Finance and Investor Relations will represent the Company in a session scheduled for 3:00 pm Eastern Time. A simultaneous webcast and replay of the Company’s presentation will be available on Stryker’s website at . The webcast will be archi...
Stryker announces definitive agreement to acquire care.ai, a leading v...
Stryker announces definitive agreement to acquire care.ai, a leading virtual care and ambient intelligence solutions platform Portage, Michigan, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire care.ai, a privately held company specializing in delivering AI-assisted virtual care workflows, smart room technology and ambient intelligence solutions. The acquisition will strengthen Stryker’s growing healthcare IT offering and wirelessly connected medical device portfolio. This growing segment is ...
Stryker declares an $0.80 per share quarterly dividend
Stryker declares an $0.80 per share quarterly dividend Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.